PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Bought by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC boosted its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 40.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 142,039 shares of the company’s stock after purchasing an additional 41,238 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.27% of PROCEPT BioRobotics worth $11,437,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of PRCT. Swiss National Bank increased its position in shares of PROCEPT BioRobotics by 5.8% in the 3rd quarter. Swiss National Bank now owns 95,400 shares of the company’s stock valued at $7,643,000 after acquiring an additional 5,200 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of PROCEPT BioRobotics in the third quarter valued at about $1,371,000. Advisors Asset Management Inc. raised its stake in shares of PROCEPT BioRobotics by 28.8% in the third quarter. Advisors Asset Management Inc. now owns 12,350 shares of the company’s stock worth $989,000 after purchasing an additional 2,758 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of PROCEPT BioRobotics during the third quarter worth about $979,000. Finally, Charles Schwab Investment Management Inc. boosted its position in PROCEPT BioRobotics by 13.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 402,565 shares of the company’s stock valued at $32,254,000 after buying an additional 46,665 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the transaction, the chief financial officer now owns 107,991 shares in the company, valued at $6,161,966.46. This represents a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,455 shares of company stock worth $368,322. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT opened at $62.53 on Wednesday. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 52 week low of $45.56 and a 52 week high of $103.81. The stock’s 50-day moving average price is $66.71 and its 200-day moving average price is $78.25. The stock has a market capitalization of $3.43 billion, a PE ratio of -32.07 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. As a group, equities analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on PRCT. Morgan Stanley decreased their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Truist Financial reaffirmed a “buy” rating and issued a $90.00 price target (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).